Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer

Summary

Novel therapeutic strategies are emerging in cancer treatment. Melanoma, colorectal and lung cancer are all cancer types subjected to a large potion of innovative drug candidates. In this 400 page report BioSeeker Group has compiled and analyzed information concerning drug development and competitive situation on three major cancer indications. The report not only provides a framework for current progress in the treatment for these cancer types but as well a careful identification and evaluation of drug candidates. BioSeeker Group has identified 155 drugs under development; many of them in late developmental stage. The activities of 170 companies are reported.

Melanoma drug development has and will continue to have a strong focus on target therapy such as vaccines, monoclonal antibodies, dendritic cells, and gene therapy. In recent years, immunologic strategies including tumor vaccine and adjuvant therapy with interferon-alfa have been attempted to improve survival of patients with more advanced malignant melanoma. Another emerging strategy in anticancer therapy is the targeting of chemotherapy resistance by overcoming the antiapoptosis mechanisms of cancer cells. An example of this approach is the novel antisense oligonucleotide Genasense that targets the antiapoptotic gene bcl-2. Recently, Genta initiated a European regulatory submission for Genasense plus chemotherapy for patients with advanced melanoma by sending a letter of intent to EMEA for Marketing Authorization Application.

Colorectal cancer is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant advances in the treatment of advanced colorectal cancer over the past 5 years. This is most prominent due to the introduction of three novel cytotoxic agents - Xeloda, Camptosar, and Eloxatin - and the recent approval of the two antibodies - Avastin and Erbitux. Interestingly, an army of novel agents and targets are currently in Phase II clinical trials, and their contributions and impact on future therapy in colorectal cancer remains to be seen.

Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced NSCLC. However, despite their contributions, science has reached a therapeutic plateau. Both Avastin and Efaproxyn have generated exciting data. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analysed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost effective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine).

This report covers the latest on:

• Disease overview, including incidence, unmet needs, risk factors, screening and diagnosis.
• Analysis of current treatments, key therapeutic strategies and combination therapies.
• Progress analysis on pipeline products, including emerging and hot pre-clinical data, discontinued projects, clinical trial information, commercial potential and limiting factors.
• Competitive landscape analysis

Scope of this report

• Thorough examination of status and impact on novel drugs in development
• Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
• Case studies on major drugs on market
• Competitive landscape assessment, companies in the field and high lightening major competitors

Key reasons to read this report

• Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for novel therapeutics and the results of clinical trials to date.
• Novel targets and agents are discussed and organized
• Gain insight into the current challenges and commercial opportunities

Contents

• 1 Executive Summary
• 2 Methodology
• 3 Table Of Contents
  • 3.1 List Of Tables
  • 3.2 List Of Boxes
  • 3.3 List Of Figures
• 4 Introduction Melanoma
  • 4.1 Etiology And Pathophysiology
• 5 Current Treatment Regimens
  • 5.1 An Overview
  • 5.2 Evaluation Of Cytotoxic Drugs
    • Dacarbazine
    • Cisplatin
    • Carboplatin
    • Carmustine
    • Melphalan
    • Paclitaxel
    • Tamoxifen
    • Temozolomide
    • Vinblastine/Vinorelbine
  • 5.3 Evaluation Of Biological Treatments
    • Virulizin
    • Melacine
    • Alfanative (Multiferon)
    • Proleukin or (Macrolin)
    • Ceplene Maxamine
• 6 Key Therapy Strategies In Development
  • 6.1 Immunotherapy
  • 6.2 Cancer Vaccines
  • 6.3 Antiangiogenesis
  • 6.4 Gene Therapy
• 7 Competitive Lanscape In Melanoma R&d
  • 7.1 Phase I & II R&d Collaborations In Melanoma: Oxxon
  • 7.2 Roche Links Schering-Plough And Chugai Clusters Together
  • 7.3 Gsk Brings Wyeth, Hayashibara, Cytokinetics And Coley Together
  • 7.4 Gsk And Sanofi-Aventis Have A Joint Middle Man
  • 7.5 R&d Collaboration Trends In Melanoma Projects
• 8 Current Melanoma Drug Development
  • 8.1 Vaccines: Active Immunotherapy A Benefit Or Not?
    • Vaccine: Direct Immunization with Tumor Antigens
      • 8.1.1.1 Progress Analysis: Oncophage
      • 8.1.1.2 Progress Analysis: GMK
      • 8.1.1.3 Progress Analysis: NOVOVAC-M1
      • 8.1.1.4 Progress Analyses: SB 249553
      • 8.1.1.5 Progress Analysis: MJV 101
      • 8.1.1.6 Progress Analysis: A Russian Melanoma Vaccine
      • 8.1.1.7 Progress Analysis: GV 1001
      • 8.1.1.8 Progress Analyses: Elea Vaccine
      • 8.1.1.9 Progress Analysis: NY-ESO-1 ISCOMS
      • 8.1.1.10 Progress Analysis: F 50040
      • 8.1.1.11 Progress Analysis: Transvax Vaccines: Is the Development of Cell Therapy Stalling?
      • 8.1.1.12 Progress Analysis: Canvaxin
      • 8.1.1.13 Progress Analysis: Dexosome
      • 8.1.1.14 Progress Analysis: M-VAX ORGINAL
      • 8.1.1.15 Progress Analysis: OncoVax
      • 8.1.1.16 Progress Analysis: Uvidem DNA Vaccine
      • 8.1.1.17 Progress Analysis: Alvac-Mage1/Mage3
      • 8.1.1.18 Progress Analysis: Oxxon Vaccine
      • 8.1.1.19 Progress Analysis: Therion's Melanoma Vaccine
      • 8.1.1.20 Progress Analysis: ImmunoVex trimelan
      • 8.1.1.21 Progress Analysis: OncoVEXGM-CSF
      • 8.1.1.22 Progress Analysis: GVAX
      • 8.1.1.23 Progress Analysis: Gp100 + MART-1
      • 8.1.1.24 Progress Analysis: MAGE-3-TK OR M3TK Optimism for New Vaccine Adjuvants
      • 8.1.1.25 Progress Analysis: Enhanzyn
      • 8.1.1.26 Progress Analysis: QS-21
      • 8.1.1.27 Progress Analysis: Zadaxin
      • 8.1.1.28 Progress Analysis: Mobista
      • 8.1.1.29 Progress Analysis: ProMune
      • 8.1.1.30 Progress Analysis: Talabostat
  • 8.2 Immunostimulants: The Push In Passive Immunotherapy Immuno-Biologicals: The Work Horse
    • 8.2.1.1 Progress Analysis: MDX-010
    • 8.2.1.2 Progress Analysis: Peginterferon alfa-2b
    • 8.2.1.3 Progress Analysis: Iboctadekin
    • 8.2.1.4 Progress Analysis: BAY 504798
    • 8.2.1.5 Progression Analysis: EMD 273063
    • 8.2.1.6 Progress Analysis: Urocidin
    • 8.2.1.7 Progress Analysis: CP-675206 Immunostimulation by Gene Therapy
    • 8.2.1.8 Progress Analysis: ALLOVECTIN-7
    • 8.2.1.9 Inovio Biomedical & Lee Moffitt Cancer Center Make a Joint move in Gene therapy
    • 8.2.1.10 Progress Analysis: TG 1041 One Small Molecular Drug Candidate
    • 8.2.1.11 Progress Analysis: Lenalidomide
  • 8.3 Antiangiogenesis- The Major Focus For The Next Decade?
    • 8.3.1.1 Progress Analysis: Sorafenib
    • 8.3.1.2 Progress Analysis: Vitaxin
    • 8.3.1.3 Progress Analysis: Avastin
    • 8.3.1.4 Progress Analysis: Endostatin
    • 8.3.1.5 Progress Analysis: PI 88
  • 8.4 Apoptosis Inducers: Moving Into Market
    • 8.4.1.1 Progress Analysis: Genasense
    • 8.4.1.2 Progress Analysis: Didemnin B
    • 8.4.1.3 Progress Analysis: INGN 241
    • 8.4.1.4 Progress Analysis: KOS 953
  • 8.5 Small Molecules Inhibiting Cell Growth Faces Difficulties
    • 8.5.1.1 Progress Analysis: Temozolomide
    • 8.5.1.2 Progress Analysis: Pivanex
    • 8.5.1.3 Progress Analysis: Karenitecin
    • 8.5.1.4 Progress Analysis: Lomeguatrib
    • 8.5.1.5 Progress Analysis: PD 0325901
    • 8.5.1.6 Progress Analysis: SB 715992
    • 8.5.1.7 Progress Analysis: INO 1001
    • 8.5.1.8 Progress Analysis: CP 4055
  • 8.6 Other Biological Drugs
    • 8.6.1.1 Progress Analysis: AP 12009
    • 8.6.1.2 Progress Analysis: Ecromeximab
    • 8.6.1.3 Progress Analysis: ILX 651
    • 8.6.1.4 Progress Analysis: Kahalalide F
    • 8.6.1.5 Progress Analysis: ABX MA1
• 9 Treatment Guide Lines Melanoma
• 10 Introduction Colorectal Cancer
• 11 Epidemiology
  • 11.1 Disease Definition
  • 11.2 Prognosis For Colorectal Cancer By Stage
• 12 Progress On Current Treatment Strategies
  • 12.1 Capecitabine
  • 12.2 Irinotecan
  • 12.3 Bevacizumab
  • 12.4 Oxaliplatin
  • 12.5 Cetuximab
  • 12.6 Levamisole
• 13 Key Drug Strategies In Crc
  • 13.1 Apoptosis
    • An Answer To Drug Resistance
    • Novel Therapies At The Gate
  • 13.2 Tumor Vascularization & Antivascular Agents
    • Anti-Angiogenesis: Therapeutic Strategies
    • Single Agent Therapy: Poorly Active In Advanced Tumors
    • Synergistic Effects With Cytotoxic Therapies
    • Vascular Targeting Agents
  • 13.3 Vaccines
    • Tumor antigens
    • The Cell Vaccines Strategy
    • Potent antigen presenting cells
    • Emerging strategies
    • Better-characterized antigens
• 14 Competitive Landscape In Crc Drug Development
  • 14.1 We Are In The Lead
    • Amgen
    • Novartis and Schering
    • OSI, Genentech, Hoffmann La Roche & Pfizer
    • Sanofi-Aventis
• 15 Current Crc Drug Development
  • 15.1 Chemotherapy And Cytotoxic Drugs - A Strategy Reborn
    • Progress Analysis: CoFactor
    • Progress Analysis: Trabectedin (ET-743)
    • Progress Analysis: Pemetrexed
    • Progress Analysis: TS-1
    • Progress Analysis: Edotecarin
    • Progress Analysis: Aroplatin
    • Progress Analysis: Ixabepilone
  • 15.2 EGF-R Inhibition And Other Signal Transduction Inhibitors
    • Progress Analysis: Panitumumab
    • Progress Analysis: Erlotinib (Tarceva)
    • Progress Analysis: Gefitinib (Iressa)
    • Progress Analysis: Pelitinib
    • Progress Analysis: Sorafenib
  • 15.3 Signal Transduction Inhibitors In CRC
    • Progress Analysis: BIO-117
    • Progress Analysis: PD 0325901
  • 15.4 Antiangiogenetic- A Team Of Players
    • Progress Analysis: Vatalanib
    • Progress Analysis: Thalidomide
    • Progress Analysis: AMG 706
    • Progress Analysis: Combretastatin A4 prodrug
    • Progress Analysis: MBT 0206
    • Progress Analysis: MEDI 522
    • Progress Analysis: Tetrathiomolybdate
    • Progress Analysis: WX-UK1
  • 15.5 COX-2 Inhibitors - What Will Become Of Us?
    • Progress Analysis: P 54
    • Progress Analysis: CV-247
  • 15.6 Apoptosis: An Approach With A Future
    • Progress Analysis: HGS-ETR1
    • Progress Analysis: APLIDIN
    • Progress Analysis: VELCADE
    • Progress Analysis: TELCYTA
    • Progress Analysis EPO 906
    • Progress Analysis: BIO-145
    • Progress Analysis: Genasense
    • Progress Analysis: Rexin-G
    • Progress Analysis: Indisulam
    • Progress Analysis: Seliciclib
    • Progress Analysis: SYMADEX
  • 15.7 Necrotic Cell Death Inducers
    • Progress Analysis: RAV12
    • Progress Analysis: Cantuzumab mertansine
    • Progress Analysis: HuC242-DM4
    • Progress Analysis: COTARA
  • 15.8 Vaccines: A High Threshold To Success
    • Cell Vaccine
      • 15.8.1.1 Progress Analysis: OncoVAX
      • 15.8.1.2 Progress Analysis CANVAXIN
      • 15.8.1.3 Progress analysis Collidem
      • 15.8.1.4 Progress Analysis Dendricell
      • 15.8.1.5 Progress Analysis: Neuvenge
      • 15.8.1.6 Progress Analysis: Onyvax-CR
      • 15.8.1.7 Progress Analysis: Ras-VAX
    • Vaccine: Direct Immunization with Protein and peptides
      • 15.8.1.8 Progress Analysis Avicine
      • 15.8.1.9 Progress Analysis: Oncophage
      • 15.8.1.10 Progress Analysis EP 2101
      • 15.8.1.11 Progress Analysis: MSI vaccine
      • 15.8.1.12 Progress Analysis: Corixa's MUC-1 vaccine
      • 15.8.1.13 Progress Analysis: GV1002
    • Anti-idiotype Monoclonal Antibodies
      • 15.8.1.14 Progress Analysis: CeaVac
      • 15.8.1.15 Progress Analysis: Onyvax-105
    • DNA and Virally Encoded Vaccines
      • 15.8.1.16 Progress Analysis: TroVax
      • 15.8.1.17 Progress Analysis: ALVAC-CEA-B7.1
      • 15.8.1.18 Progress Analysis CEA-TRICOM
      • 15.8.1.19 Progress Analysis IR 705
      • 15.8.1.20 Progress analysis HYB-2055
    • Passive Immunotherapy and Conjugated Antibodies
      • 15.8.1.21 Progress Analysis: IGN 101
      • 15.8.1.22 Progress Analysis: CEA-Cide
      • 15.8.1.23 Progress Analysis: LMB 9
      • 15.8.1.24 Progress Analysis: XR 303
      • 15.8.1.25 Progress Analysis ING-1
  • 15.9 Immuno-Modulators
    • Progress Analysis: Dacogen
    • Progress Analysis: GCAN-101
    • Progress Analysis: ZYC300
    • Progress Analysis: Clofarabine
  • 15.10 Oncolytic Virotherapy In CRC - A Team Of Four
    • Progress Analysis: OncoVEX
    • Progress Analysis: Oncolytic HSV
• 16 Treatment Guide Lines Colorectal Cancer
  • Medical Therapy of Colorectal Cancer
• 17 Introduction Lung Cancer
  • 17.1 Current Treatment Strategies
  • 17.2 Disease Definition
  • 17.3 Etiology & Pathophysiology
  • 17.4 Prognosis
  • 17.5 Epidemiology
• 18 Progress In Current Treatment Strategies
  • 18.1 Docetaxel
  • 18.2 Vinorelbine
  • 18.3 Gemcitabine
  • 18.4 Paclitaxel
  • 18.5 Pemetrexed
  • 18.6 Gefitinib
  • 18.7 Erlotinib
• 19 Key Drug Strategies In Lung Cancer
  • 19.1 Apoptosis
  • 19.2 Antiangiogenesis And Antivascular Agents
    • Egfr And Vegfr As Target
  • 19.3 Immunotherapy
• 20 Competitive Landscape: The Late Stage Pipeline
  • 20.1 Kinase Inhibitors
    • Progress analysis: Lapatinib
    • Progress analysis: Zactima
    • Progress analysis: Affinitak
    • Progress analysis: Neovastat
  • 20.2 The Antibodies
    • Progress analysis: Bevacizumab
    • Progress analysis: Cetuximab
    • Progress analysis: Trastuzumab
    • Progress analysis: IGN-101
    • Progress analysis: Panitumumab
    • Progress analysis: Mitumomab
  • 20.3 Apoptotic Inducers
    • Progress analysis: Genasense
    • Progress analysis: Canfosfamide
    • Progress analysis: APTOSYN
    • Progress analysis: CI-994
  • 20.4 Other Strategies
    • Progress analysis: Carboxyamidotriazole
    • Progress analysis: Efaproxiral
    • Progress analysis: Tirapazamine
    • Progress analysis: Xcytrin
    • Progress analysis: Thymalfasin
    • Progress analysis: Targretin
    • Progress analysis: Vinflunine
• 21 Treatment Guide Lines Lung Cancer*
  • 21.1 References
• 22 Disclaimer
• 23 Drug Index
• 24 Company Index
• List of Tables
  • Table 1: Critical Risk Factors for Development of Melanoma
  • Table 2: Definition and Description of Stages of Melanoma
  • Table 3: Prognosis of the 4 Stages of Malignant Melanoma
  • Table 4: Current Cytotoxic Drugs for Treatment of Melanoma
  • Table 5: Development Milestones- Virulizin
  • Table 6: Development Milestones - Melacine
  • Table 7: Development Milestones - Alfanative
  • Table 8: Development Milestones - Proleukin
  • Table 9: Deployed Strategies for Blocking Angiogenesis
  • Table 10: Number of Collaborations and Drugs per Developmental Stage
  • Table 11: Tumor antigen
  • Table 12: In vivo gene therapy
  • Table 13: Cell therapy based platform in pipeline as potential treatment of melanoma
  • Table 14: Ex vivo gene therapy loading of antigen presenting cells
  • Table 15: Overview of Immunostimulants in Development based on Type
  • Table 16: Overview of Immuno-Biologicals
  • Table 17: MDX-010's Collaborative History and Landscape
  • Table 18: Overview of Gene Therapy Drugs for Immunostimulation
  • Table 19: Anti-angiogenisis Drugs under Development
  • Table 20:Selected Regulatory Progress of Sorafenib
  • Table 21: Overview Apoptopic Inducer Drugs
  • Table 22: Selected Regulatory Progress of Didemin B
  • Table 23: Overview of Small Molecule Drugs
  • Table 24: Overview of Various Biological Drugs in Development for Melanoma
  • Table 25: 5-year Survival Rate in CRC
  • Table 26: Risk Factors for Colon Cancer Development
  • Table 27: Summary of Colorectal Cancer Regimens
  • Table 28: Summary of Chemotherapy Drugs
  • Table 29: Capecitabine - Major Developmental Milestones
  • Table 30: Ironotecan - Major Developmental Milestones
  • Table 31: Bevacizumab - Major Developmental Milestones
  • Table 32: Sales Predictions on Bevacizumab
  • Table 33: Oxaliplatin - Major Developmental Milestones
  • Table 34: Cetuximab - Major Developmental Milestones
  • Table 35: Sales Predictions on Cetuximab
  • Table 36: Common Gene/Protein Defects in Apoptotic Pathways
  • Table 37: A Selection of Apoptosis Targets in Development
  • Table 38: Selection of VTA agents under clinical development as cancer therapeutics
  • Table 39: Colorectal Cancer Vaccines in Development
  • Table 40: The Representation of Investigators in the CRC Drug Pipeline
  • Table 41: Drugs with Four or more Investigators
  • Table 42: Phase III Competitors
  • Table 43: Industrial Investigators with the Highest Number of CRC Drugs in Phase I to Phase III development
  • Table 44: Phase I -Phase III Chemotherapy and Cytotoxic Drugs in Development
  • Table 45: Phase I-Phase III EGF-R Inhibitors as CRC Therapeutics
  • Table 46: Phase I-Phase III Signal Transduction Inhibitors in CRC
  • Table 47: Phase I - Phase III Antiangiogenic Drugs in Development
  • Table 48: Current COX-2 Inhibitors in Development
  • Table 49: Apoptotic Cell Death Inducers in Development
  • Table 50: Necrotic Cell Death Inducers in Development
  • Table 51 Cell therapy based platform in pipeline as potential treatment of colorectal cancer
  • Table 52: Protein/peptide vaccine as potential treatment of colorectal cancer
  • Table 53: Anti-idiotype monoclonal antibodies
  • Table 54: Nucleic acid and virally encoded vaccines
  • Table 55: Monoclonal Antibodies
  • Table 56: Immuno-modulators in CRC
  • Table 57: Chemotherapeutic drugs for treatment of NSCLC
  • Table 58. Near Term Approved Drugs for the Treatment of NSCLC
  • Table 59: Chemotherapy Drugs off Patent
  • Table 60 Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
  • Table 61 VTA agents under development
  • Table 62 EGFR or VEGFR inhibitors
  • Table 63: FMS-like tyrosine kinases and their Synonyms
  • Table 64: Fms-related Tyrosine Kinase Targets in Development
  • Table 65: Protein Kinase Targets in Clinical Trials for Lung Cancer
  • Table 66 Cancer immunotherapy strategies
  • Table 67 Recently presented studies Lapatinib
  • Table 68 Recently presented studies ZD-6474
  • Table 69 Recently presented studies bevacizumab
  • Table 70 Recently presented studies cetuximab
  • Table 71 Recently presented studies Panitumumab
  • Table 72 Recently presented studies Genasense
  • Table 73 Recently presented studies Xcytrin
  • Table 74 Recently presented studies bexarotene
  • Table 75 Recently presented studies vinflunine
• List of Boxes
  • Box 1: Mechanisms which tumor cells use to evade an immune reaction
  • Box 2: Introgen's INGN 241 Shows Vaccine Properties
  • Box 3: Quick Facts - Oncophage
  • Box 4: Oncophage - Designation and Status
  • Box 5: Quick Facts - GM2-KLH Vaccine
  • Box 6 Progenics reaquires rights to vaccine
  • Box 7: Completed Melanoma Phase III trials
  • Box 8: Quick Facts - NovaVac-M1
  • Box 9: Quick Facts - SB 249553
  • Box 10: Quick Facts - MJV 101
  • Box 11: Quick Facts - Russian Melanoma Vaccine
  • Box 12: Quick Facts - GV 1001
  • Box 13: Quick Facts - N-Acetyl-GM3 ganglioside
  • Box 14: Quick Facts: neu-glycolyl-GM3 ganglioside
  • Box 15: Quick Facts - NY-ESO-1 ISCOMS
  • Box 16 NY-ESO-1 and ISCOMATRIX
  • Box 17: Quick Facts - F 50040
  • Box 18: KpOmpA technology
  • Box 19: Quick Facts - TransVax
  • Box 20: Quick Facts - Canvaxin
  • Box 21: Canvaxin - Designation and Status
  • Box 22: CancerVax Milestone payment
  • Box 23: Quick Facts - Dexosome
  • Box 24: Important Milestones and License Fees
  • Box 25: Quick Facts - M-VAX
  • Box 26: Quick Facts -OncoVax
  • Box 27: Quick Facts - Uvidem
  • Box 28: Agreements Between Sanofi-Aventis and IDM
  • Box 29: Quick Facts - Alvac-Mage1/Mage3
  • Box 30: Quick Facts - Oxxon vaccine
  • Box 31: Quick Facts - Therion's Melanoma Vaccine
  • Box 32: Quick Facts - ImmunoVEX trimelan
  • Box 33: Quick Facts - OncoVEX GM-CSF
  • Box 34: Quick Facts - GVAX
  • Box 35: Agreement Japan Tobacco and Cell Genesys
  • Box 36: Predicted launch of GVAX
  • Box 37: Quick Facts - Gp100 + MART-1 vaccine
  • Box 38: Quick Facts - MAGE-3-TK
  • Box 39: Quick Facts - Enhanzyn
  • Box 40: Quick Facts - QS-21
  • Box 41: Quick Facts - ZADAXIN
  • Box 42: Quick Facts - Mobista
  • Box 43: Quick Facts - ProMune
  • Box 44: Quick Facts - Talabostat
  • Box 45: Quick Facts - MDX-010
  • Box 46: Quick Facts - Peginterferon alfa-2b
  • Box 47:Quick Facts - BAY-504798
  • Box 48: Quick Facts - EMD-273063
  • Box 49: Quick Facts - Urocidin
  • Box 50:Quick Facts - CP-675206
  • Box 51: Quick Facts - ALLOVECTIN-7
  • Box 52: Quick Facts - Cytokine, Gene therapy
  • Box 53: Quick Facts - TG 1041
  • Box 54: Quick Facts - Lenalidomide
  • Box 55: Introgen's INGN 241 Shows Anti-angiogenesis Properties
  • Box 56: Quick Facts - Sorefenib
  • Box 57: Quick Facts - Vitaxin
  • Box 58: Quick Facts . Bevacizumab
  • Box 59: Quick Facts - Endostatin
  • Box 60: Quick Facts - PI88
  • Box 61: Quick Facts - Oblimersen
  • Box 62: Quick Facts - Didemnin B
  • Box 63: Quick Facts - INGN 241
  • Box 64: Recent Identification of Molecular Pathways Underlying Activity of Introgen's INGN 241 Anti- Cancer Therapy
  • Box 65: Quick Facts - KOS 953
  • Box 66: Quick Facts - Temozomide
  • Box 67: Molecular Pathways Underlying the Activity of Temozolomide's Anti-Cancer Therapy
  • Box 68: Quick Facts - Pivanex
  • Box 69: Quick Facts - Karenitecin
  • Box 70: Quick Facts - Lomeguatrib
  • Box 71: Quick Facts - PD 0325901
  • Box 72: Quick Facts - SB 715992
  • Box 73: Quick Facts - INO 1001
  • Box 74: Quick Facts - CP 4055
  • Box 75: Quick Facts - AP 12009
  • Box 76: Quick Facts - Ecromeximab
  • Box 77: Quick Facts - ILX 651
  • Box 78: Quick Facts - Kahalalide F
  • Box 79: Quick Facts - ABX MA1
  • Box 80:Example of Observed Efficacy in preclinical models
  • Box 81: Anti-angiogenesis: Therapeutic strategies
  • Box 82: Anti-angiogenesis: Problems that has to be solved.
  • Box 83: Mechanisms which tumor cells use to evade an immune reaction
  • Box 84: Quick Facts - ANX-510
  • Box 85: Quick Facts - Trabectedin
  • Box 86: Quick Facts - Pemetrexed
  • Box 87: Quick Facts - TS-1
  • Box 88: Quick Facts - Edotecarin
  • Box 89: Quick Facts - Aroplatin
  • Box 90: Quick Facts - Ixabepilone
  • Box 91: Quick Facts - Panitumumab
  • Box 92: Quick Facts - Erlotinib
  • Box 93: Scientific Data on Erlotinib
  • Box 94: Quick Facts - Gefitinib
  • Box 95: Scientific Data on Gefitinib
  • Box 96: Quick Facts - Pelitinib
  • Box 97: Quick Facts - Sorafenib
  • Box 98: Quick Facts - BIO-117
  • Box 99: Quick Facts - PD 0325901
  • Box 100: Quick Facts - Vatalanib
  • Box 101: Quick Facts - Thalomide
  • Box 102: Quick Facts - AMG 706
  • Box 103: Quick Facts - Combretastatin
  • Box 104: Quick Facts - MBT 0206
  • Box 105: Quick Facts - MEDI 522
  • Box 106: Quick Facts - Tetrathiomolybdate
  • Box 107: Quick Facts - WX-UK1
  • Box 108: Quick Facts - P 54
  • Box 109: Quick Facts - CV-247
  • Box 110: Targets for Apoptosis Directed Therapy
  • Box 111: Selection of Patents Relating to Apoptosis
  • Box 112: Quick Facts - HGS-ETR1
  • Box 113: Quick Facts - APLIDIN
  • Box 114: Quick Facts - VELCADE
  • Box 115: Millennium's License Agreement with Ortho Biotech
  • Box 116: Quick Facts - TELCYTA
  • Box 117: Quick Facts - EPO 906
  • Box 118: Quick Facts - BIO-145
  • Box 119: Quick Facts - Genasense
  • Box 120: Quick Facts - Rexin-G
  • Box 121: Quick Facts - Indisulam
  • Box 122: Quick Facts - Seliciclib
  • Box 123: Quick Facts - SYMANDEX
  • Box 124: Quick Facts - RAV12
  • Box 125: Quick Facts - Cantuzumab mertansine
  • Box 126: Quick Facts - HuC242-DM4
  • Box 127: Quick Facts - Cotara
  • Box 128: Quick Facts - OncoVAX
  • Box 129: Quick Facts - Canvaxin
  • Box 130: Quick Facts - Collidem
  • Box 131: Quick Facts - Dendricell
  • Box 132: Quick Facts - Neuvenge
  • Box 133: Quick Facts - Onyvax-CR
  • Box 134: Quick Facts - Ras-VAX
  • Box 135: Quick Facts - Avicine
  • Box 136: Quick Facts - Oncophage
  • Box 137: Quick Facts - EP 2101
  • Box 138: Quick Facts - MSI Vaccine
  • Box 139: Quick Facts - MUC-vaccine
  • Box 140: Quick Facts - OncoVAX
  • Box 141: Quick Facts - CeaVac
  • Box 142: Quick Facts - Onyvax-105
  • Box 143: Quick Facts - TroVax
  • Box 144: Quick Facts - ALVA-CEA-B7.1
  • Box 145: Quick Facts - CEA-TRICOM
  • Box 146: Quick Facts - IR 705
  • Box 147 Quick Facts - Amplivax
  • Box 148: Quick Facts - IGN 101
  • Box 149: Quick Facts - CEA-Cide
  • Box 150: Quick Facts - LMB 9
  • Box 151: Quick Facts - KSB 303
  • Box 152: Quick Facts - ING-1
  • Box 153: Quick Facts -Dacogen
  • Box 154: Quick Facts - GCAN-101
  • Box 155: Quick Facts - ZYC300
  • Box 156: Quick Facts - Clofarabine
  • Box 157: Quick Facts - OncoVEX
  • Box 158: Quick Facts - NV 1020
  • Box 159: Scientific Data on Docetaxel
  • Box 160: Quick Facts - Vinorelbine
  • Box 161: Scientific Data on Vinorelbine
  • Box 162: Quick Facts - Gemcitabine
  • Box 163: Scientific Data on gemcitabine
  • Box 164: Scientific Data on Pemetrexed
  • Box 165: Quick Facts - pemetrexed
  • Box 166: Quick Facts - Gefitinib
  • Box 167: Scientific Data on Gefitinib
  • Box 168: Quick Facts - Erlotinib
• List of Figures
  • Figure 1. Oxxon's R&D Collaborations in Melanoma
  • Figure 2. Schering Plough's R&D Collaborations in Melanoma
  • Figure 3. GlaxoSmithKline and Wyeth's R&D Collaborations in Melanoma
  • Figure 4. Bristol-Myers Squibb's and Sanofi-Aventis' Collaborations in Melanoma
  • Figure 5: Summarized Description of Colon Cancer Development and Clinical Outcome.